# 大型语言模型能否设计生物武器？评估Moremi Bio的能力

发布时间：2025年05月22日

`LLM应用` `药物研发` `生物安全`

> Can Large Language Models Design Biological Weapons? Evaluating Moremi Bio

# 摘要

> 人工智能，特别是大型语言模型（LLMs），在药物研发领域取得了突破性进展，将研发周期缩短了高达40%，同时显著提升了分子靶点识别能力。然而，这些技术也带来了双重用途的风险，因其可被用于设计有毒化合物。我们通过提示Moremi Bio Agent绕过安全护栏，成功设计出1020种新型有毒蛋白质和5000种有毒小分子。深入的计算毒性评估显示，所有蛋白质均具有高度毒性，其中几种与蓖麻毒素、白喉毒素及蛇毒蛋白极为相似。部分新型化合物还与多种已知有毒物质表现出相似性，包括整合素eristostatin、金属蛋白酶等。通过定量风险评估与情景分析，我们发现当前LLM驱动的生物设计管线中存在双重用途能力，并提出多层级缓解策略。此次毒性评估的结果挑战了“大型语言模型（LLMs）无法设计生物武器”的说法，进一步加剧了对LLMs在生物设计领域潜在滥用的担忧，对研发工作构成重大威胁。此类技术的易获取性，即便对于技术经验有限的个体，也引发了严重的生物安全风险。我们的研究发现凸显了建立强大治理框架与技术保障措施的迫切需求，以在生物技术创新与生物安全要求之间寻求平衡。

> Advances in AI, particularly LLMs, have dramatically shortened drug discovery cycles by up to 40% and improved molecular target identification. However, these innovations also raise dual-use concerns by enabling the design of toxic compounds. Prompting Moremi Bio Agent without the safety guardrails to specifically design novel toxic substances, our study generated 1020 novel toxic proteins and 5,000 toxic small molecules. In-depth computational toxicity assessments revealed that all the proteins scored high in toxicity, with several closely matching known toxins such as ricin, diphtheria toxin, and disintegrin-based snake venom proteins. Some of these novel agents showed similarities with other several known toxic agents including disintegrin eristostatin, metalloproteinase, disintegrin triflavin, snake venom metalloproteinase, corynebacterium ulcerans toxin. Through quantitative risk assessments and scenario analyses, we identify dual-use capabilities in current LLM-enabled biodesign pipelines and propose multi-layered mitigation strategies. The findings from this toxicity assessment challenge claims that large language models (LLMs) are incapable of designing bioweapons. This reinforces concerns about the potential misuse of LLMs in biodesign, posing a significant threat to research and development (R&D). The accessibility of such technology to individuals with limited technical expertise raises serious biosecurity risks. Our findings underscore the critical need for robust governance and technical safeguards to balance rapid biotechnological innovation with biosecurity imperatives.

[Arxiv](https://arxiv.org/abs/2505.17154)